1 HAI conference 18-11-2004 Medicines for Europe and the World Setting priorities: missing the point A rational medicines policy for Europe A rational.

Slides:



Advertisements
Similar presentations
Association Internationale de la Mutualité Europe in health: the impact of ECJ decisions on healthcare systems Willy Palm AIM Director Palma de Mallorca,
Advertisements

1 Increasing Biotech Involvement in Global Health Innovation Oxford Conference on Innovation and Technology Transfer for Global Health September 11, 2007.
Chapter 12 - Health Care Trends and Forecasts McGraw-Hill © 2010 by The McGraw-Hill Companies, Inc. All rights reserved 12-1.
Elderly participation in European Health policy and Patients Rights Teresa Petrangolini ACN Director.
JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
No rational use of drugs without access to data The European campaign for transparency in drug regulation Danielle Bardelay - La revue Prescrire HAI Europe.
A rational Medicines Policy for Europe Danielle Bardelay Medicines in Europe Forum HAI Seminar - The Hague 18 November2004.
Demand articulation in emerging technologies Wouter Boon, Ellen Moors Athena Institute, VU University Amsterdam Third International Seville Conference.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD A report prepared by WHO for the Netherlands Government by Warren Kaplan Richard Laing and Saloni TannaMarjolein.
Pricing and paying for medicines Ad Antonisse AstraZeneca BV April 2005.
¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France
World Health Organization
EU Cross-Border Care Directive from the Primary Care perspective Results of a simulation Rita Baeten Gothenburg, 3 September 2012.
The evolving role of real-world evidence to support policy and practice CADTH 2015.
Irish Presidency of the Council of the European Union January 1 st – June 30 th December 2013 Gregory Canning Health Attaché.
University of Nebraska Medical Center PRIMARY CARE Definitions Millis Commission – 1966 First-contact, continuing, and comprehensive care Institute of.
Universal Health-Care Will this Policy Benefit the United States? By Matthew Lokant.
Michelle Boudreau, Vice President, Private Markets, March 11, 2015 Presentation to CADA.
Health care system in Belgium How Belgian patients can save 1 billion euro / year and the health insurance system 1,6 billion / year …
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Enabling Health IT National Broadband Plan’s Recommendations for Health Care HIMSS10 Annual Conference March 2, 2010.
Improving the competitiveness of the pharmaceutical industry Dominique Limet Senior Vice-President and Area Director Southern and Eastern Europe.
Facts and Figures 2008 Medicines and Health Care The Norwegian Association of Pharmaceutical Manufacturers (LMI)
Conference: Generic Drugs in Turkey and the EU THE PORTUGUESE MODEL FOR STIMULATING GENERIC COMPETITION IN THE EU June 2, 2005, Ankara, Turkey Rui Santos.
1 HEALTH NEEDS AND INDUSTRIAL GOALS: What future for the research-based pharmaceutical industry in Europe? Brian AGER EFPIA AIFA Spring Conference Rome,
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
The future prospects for clinical trials in Europe Richard Torbett Chief Economist, EFPIA.
Private complementary coverage in France Role, regulation, market, and challenges Valérie PARIS – December 7th, 2006 Joint OECD / Korea Centre of Health.
ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )
Review of 2013 actions of Reimbursement Committees Pascal Apostolides Managing Director AbbVie SFEE Vice-President Athens, 27 November 2013 Athens Hilton,
“Delivering Therapeutic Agents” - Marketing and Communication Strategies of Drug Companies Safura Nantogmah.
TBS Seminar on Essential Medicines and Health Products Geneva, 29 October 2013 Matthew Jowett, PhD Senior Health Financing Specialist Dept. Health Systems.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 2 Evidence-Based Nursing: Translating Research Evidence Into Practice.
Assessment of Patient Knowledge Regarding Drugs Prescribed and Dispensed in Some Health Insurance Outpatient Clinics in Alexandria.
Margarit MELIKYAN Drug Utilization Research Group PO, Armenia, National Institute of Health Access to and Use of Medicines by Households in Armenia: Impact.
ISPOR Polish Chapter Accomplishments and plans for 2007/2008.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD: a public health approach to innovation Hans V. Hogerzeil Director, Medicines Policy and Standards WHO, Geneva.
AIFA European Conference on Clinical Research for Decision Making Sergio Dompé - Farmindustria Rome, March 30th, 2007 Access to market by new medicines.
1 10 th Annual European Scientific and Regulatory Affairs Conference New Pharmaceutical legislation: One year experience… 21 November 2006 Bernard Lemoine.
Estimation From Censored Medical Cost Baser Onur Outcomes Research and Econometrics, Medstat Bradley Cathy Department of Medicine, Michigan State University.
The International Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Brussels, June 6-8, 2007 The pharmaceutical industry and the.
NPS MEDICINEWISE Lynn Weekes Chief Executive.
1 Determining Value for Innovation and Setting Prices Richard Laing EDM/PAR WHO.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Understanding and responding to pharmaceutical promotion: A practical guide  Americas  Europe  Western Pacific  Eastern Mediterranean  Africa  South-East.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Hungarian Pharmaceutical Market Edit Varga.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
Free Delivery of Healthcare Services in Europe Some ideas based on an article published by the Association Internationale de la Mutualité in European Public.
Welcome to Seminar Unit 5: Community-based Models of Health and Wellness Robyn Hoban.
Ministry of Labour, Health and Social Affairs of Georgia Development of e-Health system in Georgia.
Disclosure UK Talking about Transparency.
Pharmaceutical Industry Funding Challenges
HEALTH ACCOUNTS FOR PORTUGAL.
Healthy Britain.
Cooperation for Better Regulation
US Early Feasibility Studies (EFS)
Disclosure UK Talking about Transparency.
Prescription for Pharmaceutical Reform: Healing an Ailing System
AGREEMENT FOR TRANSPARENCY The Case of Mexico
National Medicines Policies
Issues on Dispensing Dr Percy Mahlathi.
Kaisa Immonen EPF Director of Policy
Drug Pricing, Innovation, and the Cycle of Greed
eEurope 2005 What’s new? What’s still important?
Germany’s Approach to Prescription Drug Pricing
Realizing effective health technology assessment for the SA healthcare environment Praneet Valodia The BHF Southern African Conference July’07.
Levison L, Laing RL, Waning B, Kaplan W
National Medicines Policies
Germany’s Approach to Prescription Drug Pricing
Presentation transcript:

1 HAI conference Medicines for Europe and the World Setting priorities: missing the point A rational medicines policy for Europe A rational medicines policy for Europe Ron Hendriks, AIM President

AIM in the world (

AIM common values Access to quality health care Solidarity Selfgovernance Social profit

Association Internationale de la Mutualité 4 AIM supports the creation of public health needs based R&D agenda Priority : Prevention Health education Living and working conditions Dutch initiative on priority medicines

Association Internationale de la Mutualité 5 Price control systems: unpredictable ? they do not know how long it will take for a decision, what the final price will be and whether additional information or studies will be required…this results in an unpredictable lottery for companies who have brought a product to market through a series of regulatory hurdles and still do not know what the final reimbursed price will be. WHO report Chapter on innovation

Association Internationale de la Mutualité 6 Barriers to innovation in pharmaceutical R&D importance of comparative trials (1) private insurers and the government would set aside some fraction of their annual medicines spending to endow a new institute to provide an independent source of reputable research into comparative effectiveness and cost. WHO report Chapter on innovation

Association Internationale de la Mutualité 7 Barriers to innovation in pharmaceutical R&D importance of comparative trials (2) electronic prescription and medical databases to conduct Phase IV and/or pharmaco-epidemiologic studies in place of randomized, controlled, comparative clinical trials. The European Commission is presently discussing so-called e-prescribing and other information technology (IT) approaches as part of their interest in the information WHO report Chapter on innovation

Association Internationale de la Mutualité 8 AIM priority concerns: Non pharmaceutical prevention and health education Relative effectiveness: added therapeutic value Comparative and long-term trials Reflection on rewarding break-through innovation Rational use Permanent independent training of doctors Improved transparency and access to information Conclusions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.